Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Procarta Biosystems
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Procarta Biosystems developed a preclinical pipeline of oligonucleotide-based antibacterial agents ("oligonucleotide antimicrobials") using transcription factor decoy oligonucleotides delivered by nanoparticles to kill multidrug-resistant Gram-negative bacteria, with lead asset PRO-202 targeting carbapenem-resistant Enterobacteriaceae for complicated urinary tract and intra-abdominal infections, but the company was dissolved in 2023 and has no reported clinical-stage assets.[1][3][6]
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Synthetic oligonucleotideNanoparticleRNA therapy
- Industry
- Biotech
02
Partnerships
CARB-XNovo Holdings REPAIR Impact Fund
Beyond the preview
Go deeper on Procarta Biosystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Procarta Biosystems.